TGF-β Receptor Inactivation and Mutant Kras Induce Intestinal Neoplasms in Mice via a β-Catenin-Independent Pathway

Gastroenterology

Volumn 136, Issue 5, 2009, Pages

  Trobridge, Patty ^a   Knoblaugh, Sue ^a   Washington, M Kay ^b   Munoz, Nina M ^a   Tsuchiya, Karen D ^a,c,d   Rojas, Andres ^a,e   Song, Xiaoling ^a   Ulrich, Cornelia M ^a   Sasazuki, Takehiko ^f   Shirasawa, Senji ^f   Grady, William M ^a,c,g  

^a Fred Hutchinson Cancer Research Center   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d SEATTLE CHILDREN S HOSPITAL   (United States)

^e Departments of Cancer Biology   (United States)

^f FUKUOKA UNIVERSITY   (Japan)

^g DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN P15; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL LEVEL; CELL PROLIFERATION; COLON ADENOCARCINOMA; COLORECTAL TUMOR; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; GENE ACTIVATION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; ONCOGENE K RAS; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

EID: 65249153611     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2009.01.066     Document Type: Article

References (37)

1. Suzuki H., Watkins D.N., Jair K.W., et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 36 (2004) 417-422
2. Grady W.M., and Markowitz S.D. Genetic and epigenetic alterations in colon cancer. Ann Rev Genomics Hum Genet 3 (2002) 101-128
3. Parsons D.W., Wang T.L., Samuels Y., et al. Colorectal cancer: mutations in a signalling pathway. Nature 436 (2005) 792
4. Grady W.M., Rajput A., Myeroff L., et al. Mutation of the type II transforming growth factor-β receptor is coincident with the transformation of human colon adenomas to malignant carcinomas. Cancer Res 58 (1998) 3101-3104
5. Munoz N., Upton M., Rojas A., et al. Transforming growth factor β receptor type II inactivation induces transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 66 (2006) 9837-9844
6. Haigis K.M., Kendall K.R., Wang Y., et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat Genet 40 (2008) 600-608
7. Sansom O.J., Meniel V., Wilkins J.A., et al. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proc Natl Acad Sci U S A 103 (2006) 14122-14127
8. Biswas S., Chytil A., Washington K., et al. Transforming growth factor b receptor type ii inactivation promotes the establishment and progression of colon cancer. Cancer Res 64 (2004) 4687-4692
9. Ijichi H., Chytil A., Gorska A.E., et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-β signaling in cooperation with active Kras expression. Genes Dev 20 (2006) 3147-3160
10. Grady W.M., Myeroff L.L., Swinler S.E., et al. Mutational inactivation of transforming growth factor-β receptor type II in microsatellite stable colon cancers. Cancer Res 59 (1999) 320-324
11. Bierie B., and Moses H.L. TGF-β and cancer. Cytokine Growth Factor Rev 17 (2006) 29-40
12. Attisano L., and Labbe E. TGF-β and Wnt pathway cross-talk. Cancer Metastasis Rev 23 (2004) 53-61
13. Massague J., Blain S.W., and Lo R.S. TGF-β signaling in growth control, cancer, and heritable disorders. Cell 103 (2000) 295-309
14. Chytil A., Magnuson M., Wrigth C., et al. Conditional inactivation of the TGF-b type II receptor using Cre:Lox. Genesis 32 (2002) 73-75
15. Madison B.B., Dunbar L., Qiao X.T., et al. cis Elements of the Villin gene control expression in restricted domains of the vertical (crypt) and horizontal (duodenum, cecum) axes of the intestine. J Biol Chem 277 (2002) 33275-33283
16. Jackson E.L., Willis N., Mercer K., et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15 (2001) 3243-3248
17. Markowitz S., and Roberts A. Tumor supressor activity of the TGF-β pathway in human cancers. Cytokine Growth Factor Rev 7 (1996) 93-102
18. Shirasawa S., Furuse M., Yokoyama N., et al. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260 (1993) 85-88
19. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
20. Collado M., Gil J., Efeyan A., et al. Tumour biology: senescence in premalignant tumours. Nature 436 (2005) 642
21. Glick A.B., Weinberg W.C., Wu I.H., et al. Transforming growth factor β 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb. (published erratum appears in Cancer Res 1997;57:2079). Cancer Res 56 (1996) 3645-3650
22. Glick A., Popescu N., Alexander V., et al. Defects in transforming growth factor-β signaling cooperate with a Ras oncogene to cause rapid aneuploidy and malignant transformation of mouse keratinocytes. Proc Natl Acad Sci U S A 96 (1999) 14949-14954
23. Bruder C.E., Piotrowski A., Gijsbers A.A., et al. Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am J Hum Genet 82 (2008) 763-771
24. Grady W.M., Parkin R.K., Mitchell P.S., et al. Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene 27 (2008) 3880-3888
25. Lee D., Pearsall R.S., Das S., et al. Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage. Mol Cell Biol 24 (2004) 8907-8916
26. Boon K., Osorio E.C., Greenhut S.F., et al. An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A 99 (2002) 11287-11292
27. Biswas S., Trobridge P., Romero-Gallo J., et al. Mutational inactivation of TGFBR2 in microsatellite unstable colon cancer arises from the cooperation of genomic instability and the clonal outgrowth of transforming growth factor β resistant cells. Genes Chromosomes Cancer 47 (2008) 95-106
28. Tuveson D.A., Shaw A.T., Willis N.A., et al. Endogenous oncogenic K-ras (G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 5 (2004) 375-387
29. Calcagno S.R., Li S., Colon M., et al. Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon. Int J Cancer 122 (2008) 2462-2470
30. Malumbres M., and Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1 (2001) 222-231
31. Ortega S., Malumbres M., and Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602 (2002) 73-87
32. Bhowmick N.A., Chytil A., Plieth D., et al. TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303 (2004) 848-851
33. Letterio J.J. TGF-β signaling in T cells: roles in lymphoid and epithelial neoplasia. Oncogene 24 (2005) 5701-5712
34. Bhowmick N.A., Ghiassi M., Bakin A., et al. Transforming growth factor-b1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Mol Biol Cell 12 (2001) 27-36
35. Janssen K.P., Alberici P., Fsihi H., et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 131 (2006) 1096-1109
36. Baba I., Shirasawa S., Iwamoto R., et al. Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. Cancer Res 60 (2000) 6886-6889
37. Khambata-Ford S., Garrett C.R., Meropol N.J., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25 (2007) 3230-3237